Author: Editor

Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome. Read here: https://meetinglibrary.asco.org/record/186876/abstract

Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome. Read here: https://meetinglibrary.asco.org/record/186876/abstract

Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome. Read here: https://meetinglibrary.asco.org/record/186876/abstract

Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. https://library.ehaweb.org/eha/2020/eha25th/303390/courtney.dinardo.a.randomized.double-blind.placebo-controlled.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Ddinardo

Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. https://library.ehaweb.org/eha/2020/eha25th/303390/courtney.dinardo.a.randomized.double-blind.placebo-controlled.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Ddinardo

Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. https://library.ehaweb.org/eha/2020/eha25th/303390/courtney.dinardo.a.randomized.double-blind.placebo-controlled.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Ddinardo

Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen). Read here: https://meetinglibrary.asco.org/record/187445/abstract

Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen). Read here: https://meetinglibrary.asco.org/record/187445/abstract

Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS in EGFRm MET-amplified NSCLC. https://www.ascopost.com/issues/july-25-2020/ctdna-clearance-predicts-progression-free-survival-with-osimertinibsavolitinib-in-egfr-mutant-met-amplified-nsclc/

Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS in EGFRm MET-amplified NSCLC. https://www.ascopost.com/issues/july-25-2020/ctdna-clearance-predicts-progression-free-survival-with-osimertinibsavolitinib-in-egfr-mutant-met-amplified-nsclc/

Philadelphia, PA (July 21, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Oncoceutics’ investigational cancer drug ONC201 for the treatment of “H3 K27M-mutant glioma”.The Rare Pediatric Disease Priority Review Voucher program, which was created as part of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, is intended to incentivize the development of new therapies for rare pediatric diseases. Should ONC201 be approved by the FDA for H3 K27M-mutant glioma, the Rare Pediatric Disease Designation may enable Oncoceutics…

Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS in EGFRm MET-amplified NSCLC. https://www.ascopost.com/issues/july-25-2020/ctdna-clearance-predicts-progression-free-survival-with-osimertinibsavolitinib-in-egfr-mutant-met-amplified-nsclc/

Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen). Read here: https://meetinglibrary.asco.org/record/187445/abstract

Chadi Nabhan MD, MBA, FACP @chadinabhan of Caris Life Sciences @carisls discusses the characterizations of KRAS mutations in non-small cell lung cancer. Read here: https://meetinglibrary.asco.org/record/184890/abstract

Chadi Nabhan MD, MBA, FACP @chadinabhan of Caris Life Sciences @carisls discusses the characterizations of KRAS mutations in non-small cell lung cancer. Read here: https://meetinglibrary.asco.org/record/184890/abstract

Neelima Denduluri, MD @ndenduluri1 of Virginia Cancer Specialists @VCSpecialists discusses CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e13029

Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by platnium-based chemotherapy. Read here: https://meetinglibrary.asco.org/record/161486/abstract

Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by platnium-based chemotherapy. Read here: https://meetinglibrary.asco.org/record/161486/abstract

Philadelphia, PA (July 22, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates GBM Awareness Day this July and expresses its support for all those affected by this devastating form of brain cancer. Glioblastoma (GBM) is the most common type of malignant brain tumor among adults and is typically fatal. The two-year survival rate for GBM is less than 20%, and little progress has been made in battling brain cancer over the past 50 years. ONC201, the company’s lead development candidate, is currently being tested in clinical trials for brain cancer, including GBM. Early results for the ONC201 trials…

Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by platnium-based chemotherapy. Read here: https://meetinglibrary.asco.org/record/161486/abstract

Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072 presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/186711/abstract

Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses CX-2029, a PROBODY drug conjugate targeting CD71: Results from a first-in-human study in patients with advanced cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185085/abstract

Michael Korn, MD, CMO of Caris Life Sciences discusses the enrichment of alterations in targetable molecular pathways in KRAS wild-type pancreatic cancer. Read here: https://meetinglibrary.asco.org/record/186629/abstract

Elizabeth Swisher, MD of UW Medicine @UWMedicine discusses characterization of patients with long-term responses to rucaparib in recurrent ovarian cancer. Read here: https://meetinglibrary.asco.org/record/185449/abstract

Elizabeth Swisher, MD of UW Medicine @UWMedicine discusses characterization of patients with long-term responses to rucaparib in recurrent ovarian cancer. Read here: https://meetinglibrary.asco.org/record/185449/abstract

Adam Brufsky, MD, PhD of University of Pittsburgh Cancer Institute discusses the MINDACT and HER2 guidelines in genomic profiling for breast cancer. Read here: https://meetinglibrary.asco.org/record/188425/abstract

Adam Brufsky, MD, PhD of University of Pittsburgh Cancer Institute discusses the MINDACT and HER2 guidelines in genomic profiling for breast cancer.

Nancy U. Lin, MD of Dana-Farber Cancer Institute @DanaFarber discusses tucatinib vs. placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases Read here: https://meetinglibrary.asco.org/record/185141/abstract

Nancy U. Lin, MD of Dana-Farber Cancer Institute @DanaFarber discusses tucatinib vs. placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases Read here: https://meetinglibrary.asco.org/record/185141/abstract

Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. Read here: https://meetinglibrary.asco.org/record/187521/abstract

Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. Read here: https://meetinglibrary.asco.org/record/187521/abstract

Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. Read here: https://meetinglibrary.asco.org/record/187521/abstract

Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal breast tumors in Caucasian, African American, and Latin American patients. Read here: https://meetinglibrary.asco.org/record/190857/abstract

Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal breast tumors in Caucasian, African American, and Latin American patients. Read here: https://meetinglibrary.asco.org/record/190857/abstract

Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal breast tumors in Caucasian, African American, and Latin American patients. Read here: https://meetinglibrary.asco.org/record/190857/abstract

Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based pathways.

Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based pathways. Read here: https://meetinglibrary.asco.org/record/187164/abstract

Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based pathways. Read here: https://meetinglibrary.asco.org/record/187164/abstract

William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. Read here: https://meetinglibrary.asco.org/record/186699/abstract

William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. Read here: https://meetinglibrary.asco.org/record/186699/abstract

William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. Read here: https://meetinglibrary.asco.org/record/186699/abstract

Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses phase I/II clinical trial of autologous CMV-specific cytotoxic t-cells for GBM patients https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2014-0899.html

Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses phase I/II clinical trial of autologous CMV-specific cytotoxic t-cells for GBM patients https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2014-0899.html

Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple myeloma patients in INSIGHT MM: impact on healthcare resource utilization and overall survival. Read here: https://library.ehaweb.org/eha/2020/eha25th/294884/michael.a.thompson.global.rates.of.influenza.28fv29.and.pneumococcal.28pv29.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dinsight

Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple myeloma patients in INSIGHT MM: impact on healthcare resource utilization and overall survival. Read here: https://library.ehaweb.org/eha/2020/eha25th/294884/michael.a.thompson.global.rates.of.influenza.28fv29.and.pneumococcal.28pv29.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dinsight

Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple myeloma patients in INSIGHT MM: impact on healthcare resource utilization and overall survival. Read here: https://library.ehaweb.org/eha/2020/eha25th/294884/michael.a.thompson.global.rates.of.influenza.28fv29.and.pneumococcal.28pv29.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dinsight

Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). https://meetinglibrary.asco.org/record/185977/abstract

Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). https://meetinglibrary.asco.org/record/185977/abstract

Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma. All three abstracts were presented at this year’s virtual ASCO. Ziopharm will present updated clinical data from its Phase 1/2 controlled IL-12 program. Data will show clinical results of its IL-12 gene therapy, Ad+V, as a monotherapy and in combination with nivolumab for the treatment of recurrent glioblastoma (rGBM). Phase 1 data from this program have shown that treatment with Ad+V can double the median overall survival of patients with rGBM.

Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma. All three abstracts were presented at this year’s virtual ASCO. Ziopharm will present updated clinical data from its Phase 1/2 controlled IL-12 program. Data will show clinical results of its IL-12 gene therapy, Ad+V, as a monotherapy and in combination with nivolumab for the treatment of recurrent glioblastoma (rGBM). Phase 1 data from this program have shown that treatment with Ad+V can double the median overall survival of patients with rGBM.